Phase 1 Cytokine Release Syndrome Clinical Trials

4 recruitingPhase 1

What is a Phase 1 trial?

Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.

Showing 1–4 of 4 trials

Recruiting

Phase 1Phase 2

Study of CTO1681 for the Prevention and Treatment of CRS in DLBCL Patients Receiving CAR T-Cell Therapy

Cytokine Release Syndrome

CytoAgents, Inc.54 enrolled6 locationsNCT05905328

Recruiting

Phase 1

Adjunctive Methylene Blue for Immunotherapy-related CRS and ICANS: Phase I Study

Cytokine Release SyndromeICANS

Institute of Hematology & Blood Diseases Hospital, China18 enrolled1 locationNCT07169487

Recruiting

Phase 1

Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab

Non-Hodgkin LymphomaCytokine Release Syndrome

Taylor Brooks20 enrolled1 locationNCT06447376

Not Yet Recruiting

Phase 1

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of GP1681 in Healthy Adult Participants

Cytokine Release Syndrome (CRS)COVID-19

CytoAgents, Inc24 enrolled1 locationACTRN12620000834954